Sarepta therapeutics to share clinical update for 30 mg/kg arm of momentum study for srp-5051, its investigational ppmo for the treatment of duchenne muscular dystrophy

Cambridge, mass., april 30, 2021 (globe newswire) -- sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today announced that on monday, may 3, 2021 at 8:30 am eastern time, the company will host a webcast and conference call to present results from the 30 mg/kg arm of the momentum study, a multiple-ascending dose clinical trial of srp-5051 for the treatment of duchenne muscular dystrophy. srp-5051 is the first investigational treatment using sarepta's next-generation ppmo platform, which is designed around a proprietary cell-penetrating peptide conjugated to sarepta's phosphorodiamidate morpholino oligomer (pmo) backbone with the goal of increasing drug concentration in muscle tissue.
SRPT Ratings Summary
SRPT Quant Ranking